Cargando…

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis

BACKGROUND: This study aimed to determine associations among short- and long-acting erythropoiesis stimulating agents (ESAs), changes in serum fibroblast growth factor 23 (FGF23) and biomarkers of iron metabolism. METHODS: Among 108 patients on hemodialysis (HD), 44 received every 2 weeks or monthly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honda, Hirokazu, Tanaka, Kenji, Michihata, Tetsuo, Shibagaki, Keigo, Yuza, Toshitaka, Hirao, Keiichi, Tomosugi, Naohisa, Ganz, Tomas, Higashimoto, Yuichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986323/ https://www.ncbi.nlm.nih.gov/pubmed/33777378 http://dx.doi.org/10.1093/ckj/sfaa042

Ejemplares similares

Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis
por: Yoshida, Shunsuke, et al.
Publicado: (2023)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients
por: Honda, Hirokazu, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients
por: Ogawa, Chie, et al.
Publicado: (2020)

Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2017)

Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia
por: Olivera, Joseph, et al.
Publicado: (2023)

Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis
por: Saifan, Chadi, et al.
Publicado: (2013)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients
por: Takasawa, Kazuya, et al.
Publicado: (2014)

Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma
por: Kijima, Hiroaki, et al.
Publicado: (2008)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis
por: Nishizawa, Yoko, et al.
Publicado: (2020)

Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study
por: Ogawa, Chie, et al.
Publicado: (2017)

Fibroblast growth factor-23 levels in maintenance hemodialysis patients in India
por: Anandh, U., et al.
Publicado: (2017)

Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD
por: Sharma, Shilpa, et al.
Publicado: (2019)

TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis
por: Ganz, Tomas, et al.
Publicado: (2023)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

Prediction of hemoglobin levels in individual hemodialysis patients by means of a mathematical model of erythropoiesis
por: Fuertinger, Doris H., et al.
Publicado: (2018)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis
por: Lee, Hyang Yun, et al.
Publicado: (2022)

Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor
por: Koikawa, Kenji, et al.
Publicado: (2020)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation
por: Kawabata, Chiaki, et al.
Publicado: (2019)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Serum trace metal association with response to erythropoiesis stimulating agents in incident and prevalent hemodialysis patients
por: Brier, Michael E., et al.
Publicado: (2020)

Comparison of Patient Survival According to Erythropoiesis-Stimulating Agent Type of Treatment in Maintenance Hemodialysis Patients
por: Kang, Seok Hui, et al.
Publicado: (2023)

Diagnostic value of fibroblast growth factor 23 for abdominal aortic calcification in Indonesian hemodialysis patients
por: Muzasti, Riri Andri, et al.
Publicado: (2021)

Networking erythropoiesis
por: Kerenyi, Marc A., et al.
Publicado: (2010)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Hepcidin Expression in Iron Overload Diseases Is Variably Modulated by Circulating Factors
por: Ravasi, Giulia, et al.
Publicado: (2012)

Erythropoietin and the Regulation of Erythropoiesis
por: Mc Phedran, Peter
Publicado: (1971)

In Vitro Aspects of Erythropoiesis
por: Lord, B. I.
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_4rau3hpv8sr39g7j65058r58qd